Gilvetmab: Canine PD-1 Immunotherapy and Conditional-Licence Profile

gilvetmab is covered as caninized anti-pd-1 monoclonal antibody immune-checkpoint inhibitor, with species, evidence, regulatory, safety, interaction and monitoring boundaries for a veterinarian-led decision.

Caninized anti-PD-1 monoclonal antibody immune-checkpoint inhibitor. Gilvetmab, a caninized monoclonal antibody directed against programmed cell death protein 1 (PD-1).

Gilvetmab, a caninized monoclonal antibody directed against programmed cell death protein 1 (PD-1).

Gilvetmab binds canine PD-1 and is intended to reduce inhibitory checkpoint signalling that can restrain antitumour T-cell activity. That pharmacologic rationale does not mean every tumour is immune-responsive, and checkpoint engagement is not a patient-specific response predictor.

The USDA record identifies canine mast-cell cancer and canine melanoma. The 2026 AAHA guideline describes use for specified stages of those diseases and notes specialist-only availability. Selection therefore depends on confirmed tumour type, stage, measurable disease, prior local control, concurrent treatment and access to a veterinary oncologist.

The USDA record identifies canine mast-cell cancer and canine melanoma. The 2026 AAHA guideline describes use for specified stages of those diseases and notes specialist-only availability. Selection therefore depends on confirmed tumour type, stage, measurable disease, prior local control, concurrent treatment and access to a veterinary oncologist.

Veterinary-specialist intravenous infusion

USDA publishes the product record and a compilation of supporting safety studies. The regulatory category is a conditional veterinary biologics licence: it reflects an accepted safety package and a reasonable expectation of efficacy, not the same effectiveness standard as an unrestricted full licence. Published tables cannot be used to compare Gilvetmab directly with surgery, radiation, chemotherapy or another immunotherapy because populations and study designs differ.

Infusion reactions and systemic findings reported in the USDA compilation include lethargy, appetite change, vomiting, diarrhoea, laboratory changes and less-common serious events. AAHA notes specialist administration and antihistamine premedication. Owners should not infer causation from a study event table, but any new sign after infusion requires prompt communication with the treating service.

Checkpoint immunotherapy may sit beside surgery, radiation or other systemic treatment, but combination safety and sequence are not interchangeable across protocols. Immunosuppressive medicines, immune-mediated disease, infection, organ dysfunction and prior infusion reactions require explicit oncologist review.

Current US APHIS records list Gilvetmab under USDA veterinary biologics establishment 165A and product code 979002. AAHA describes it as USDA conditionally licensed. Conditional licensure must not be rewritten as full approval, guaranteed tumour response or authorisation outside the United States.

United States conditional veterinary-biologic licensing record verified. This audit did not establish equivalent EMA, UK VMD or APVMA authorisation.

A veterinary oncologist should document baseline diagnosis and stage, concurrent medicines, organ-function data, tumour measurements and an infusion-reaction plan. During and after each infusion, the clinic determines observation and laboratory needs. Follow-up should separately record tolerance, objective tumour status and quality of life. This page intentionally gives no patient dose or infusion schedule.